NEW YORK, Oct. 20, 2014 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Repros Therapeutics Inc. ("Repros" or the "Company") (NasdaqCM: RPRX) in connection with possible violations of federal securities laws.

To get more information, click here: http://zlk.9nl.com/repros-therapeutics-rprx. There is no cost or obligation to you.

On September 26, 2014, Repros issued a press release reporting that it had been granted a Type B Pre-NDA meeting with the FDA in the first half of November of 2014. The press release further indicated that the Company would seek guidance during this Type B meeting on its planned New Drug Application for Androxal for the treatment of secondary hypogonadism with preservation of testicular function, and that Repros believed that the NDA would be filed around the end of 2014. Then on October 17, 2014, Repros announced that there is not enough clinical information regarding Androxal to hold a Pre-NDA meeting, and the Company will instead have a Type C guidance meeting with the FDA.

If you own common stock in Repros and wish to obtain additional information, please contact Eduard Korsinsky, Esq. either via email at ek@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/repros-therapeutics-rprx.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:    
Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (866) 367-6510
www.zlk.com

Logo - http://photos.prnewswire.com/prnh/20120409/MM84375LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-the-law-firm-of-levi--korsinsky-llp-launches-an-investigation-into-possible-violations-of-federal-securities-laws-by-the-board-of-directors-of-repros-therapeutics-inc---rprx-822578129.html

SOURCE Levi & Korsinsky, LLP